GYRE COO sells shares after exercising options

GYRE THERAPEUTICS, INC.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

GYRE THERAPEUTICS, INC. Chief Operating Officer Weiguo Ye reported option exercises paired with open-market sales of common stock. On May 22 and May 26, he exercised stock options to acquire a total of 7,500 shares of common stock at an exercise price of $0.75 per share and sold 7,500 shares in open-market transactions.

The reported sale prices include $6.0800 per share for 3,500 shares and a weighted average price of $6.1001 per share for 4,000 shares, with individual trades ranging from $6.04 to $6.1051. Following these transactions, Ye’s directly held common stock position is reported at approximately 700,000 shares, indicating the activity mainly reflects option-related liquidity rather than a large change in overall ownership.

Insider Trade Summary

Exercise and Sale: 7,500 shares ($40K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Ye Weiguo

Role Chief Operating Officer

Sold 7,500 shs ($46K)

Approx. gross sale proceeds $46K

Approx. exercise cost $6K

Approx. pre-tax spread $40K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	4,000	$0.00	$0.00
Exercise	Common Stock	4,000	$0.75	$3K
Sale	Common Stock	4,000	$6.1001	$24K
Exercise	Stock Option (Right to Buy)	3,500	$0.00	$0.00
Exercise	Common Stock	3,500	$0.75	$3K
Sale	Common Stock	3,500	$6.08	$21K

Holdings After Transaction: Stock Option (Right to Buy) — 897,395 contracts (Direct); Common Stock — 700,000 shares (Direct)

Footnotes (2)

F1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.04 to $6.1051. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F2. These options are vested in full.

Key Figures

Shares sold May 26: 4,000 shares at $6.1001 Sale price range May 26: $6.04–$6.1051 per share Shares sold May 22: 3,500 shares at $6.0800 +4 more

7 metrics

Shares sold May 26 4,000 shares at $6.1001 Open-market sale of GYRE common stock on May 26, 2026

Sale price range May 26 $6.04–$6.1051 per share Price range across multiple GYRE sale transactions

Shares sold May 22 3,500 shares at $6.0800 Open-market sale of GYRE common stock on May 22, 2026

Options exercised May 22 3,500 shares at $0.75 Stock option exercise into GYRE common stock

Options exercised May 26 4,000 shares at $0.75 Stock option exercise into GYRE common stock

Shares following May 26 sale 700,000 shares Direct GYRE common stock holdings after transaction

Options remaining after May 26 897,395 options Stock options (right to buy) following derivative transaction

Key Terms

open-market sale, derivative exercise/conversion, Stock Option (Right to Buy), weighted average sale price per share, +1 more

5 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action": "derivative exercise/conversion""

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

vested in full financial

"These options are vested in full."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did GYRE COO Weiguo Ye report in this Form 4 for GYRE?

He reported exercising stock options for 7,500 GYRE shares at $0.75 each and selling 7,500 common shares in the open market, reflecting routine option exercise-and-sell activity rather than a large change in his overall ownership position.

How many GYRE common shares did the COO sell and at what prices?

He sold 3,500 GYRE common shares at $6.0800 per share and 4,000 shares at a weighted average of $6.1001, with individual sales ranging between $6.04 and $6.1051 across multiple trades on the reported dates.

What options did the GYRE COO exercise in the latest Form 4 filing?

He exercised vested stock options covering 3,500 and 4,000 underlying GYRE common shares, each with a conversion or exercise price of $0.75 per share, converting derivative positions into common stock immediately before selling equivalent share amounts.

What is Weiguo Ye’s GYRE common stock ownership after these transactions?

After the reported exercises and sales, his directly held GYRE common stock position is shown around 700,000 shares, indicating that the 7,500-share sale is small relative to his remaining holdings and represents a modest proportion of his total reported ownership.

Were the GYRE COO’s options fully vested at the time of exercise?

Yes. A footnote states that the reported stock options are vested in full, meaning all 7,500 options exercised by the GYRE Chief Operating Officer were fully exercisable when converted into common shares prior to the corresponding open-market sales.

How does the Form 4 describe the sale pricing for GYRE shares?

The filing notes that the reported $6.1001 price is a weighted average sale price, with individual trades for GYRE shares executed in a range from $6.04 to $6.1051, and indicates detailed trade breakdowns are available upon request from relevant parties.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/27/2026 - 04:01 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ye Weiguo

(Last)

(First)

(Middle)

C/O GYRE THERAPEUTICS, INC.

12730 HIGH BLUFF DRIVE, SUITE 250

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/22/2026		M		3,500	A	$0.75	703,500	D
Common Stock	05/22/2026		S		3,500	D	$6.08⁽¹⁾	700,000	D
Common Stock	05/26/2026		M		4,000	A	$0.75	704,000	D
Common Stock	05/26/2026		S		4,000	D	$6.1001	700,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.75	05/22/2026		M			3,500	⁽²⁾	10/31/2030	Common Stock	3,500	$0	901,395	D
Stock Option (Right to Buy)	$0.75	05/26/2026		M			4,000	⁽²⁾	10/31/2030	Common Stock	4,000	$0	897,395	D

Explanation of Responses:

1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.04 to $6.1051. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

2. These options are vested in full.

	/s/ Weiguo Ye	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR